The estimated Net Worth of Steven Gillis is at least 9.89 百万$ dollars as of 10 July 2023. Mr. Gillis owns over 609,090 units of VBI Vaccines stock worth over 73,030$ and over the last 11 years he sold VBIV stock worth over 9,304,973$. In addition, he makes 507,000$ as Independent Chairman of the Board at VBI Vaccines.
Steven has made over 9 trades of the VBI Vaccines stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 609,090 units of VBIV stock worth 1,004,999$ on 10 July 2023.
The largest trade he's ever made was buying 5,000,000 units of VBI Vaccines stock on 13 September 2022 worth over 350,000$. On average, Steven trades about 133,809 units every 67 days since 2013. As of 10 July 2023 he still owns at least 1,043,292 units of VBI Vaccines stock.
You can see the complete history of Mr. Gillis stock trades at the bottom of the page.
Steven H. Gillis Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Gillis has served as our Chairperson and as a member of our Board since May 2016. Dr. Gillis has served as a member of the board of directors of VBI DE and VBI US since July 2014 and December 2006, respectively. Since 2006, he has been a Managing Director of ARCH Venture Partners, or ARCH, a firm he joined in 2005. Dr. Gillis is focused on the evaluation of new life science technologies and also on the development and growth of ARCH’s biotechnology portfolio companies. In addition to serving on our Board, Dr. Gillis currently serves as a director of Takeda Pharmaceutical Co. Ltd. (NYSE: TAK), Homology Medicines, Inc. (NASDAQ: FIXX) and Pulmatrix, Inc. (NASDAQ: PULM). Dr. Gillis represents ARCH as a director and serves as Chairperson of a number of ARCH’s private biotechnology portfolio companies. Dr. Gillis was a founder and director of Corixa Corporation and served as Chief Executive Officer from its inception and as its Chairperson from 1999 until its acquisition in 2005 by GlaxoSmithKline. Prior to Corixa, Dr. Gillis was a founder and director of Immunex Corp. From 1981 until his departure in 1994, Dr. Gillis served as Immunex’s Director of Research and Development, Chief Scientific Officer, and as Chief Executive Officer of Immunex’s R&D subsidiary. Dr. Gillis was interim Chief Executive Officer of Immunex Corp. following its majority purchase by American Cyanamid Company and remained a member of the board until 1997. Amgen, Inc. acquired Immunex in 2002. Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti- CD20).
As the Independent Chairman of the Board of VBI Vaccines, the total compensation of Steven Gillis at VBI Vaccines is 507,000$. There are 5 executives at VBI Vaccines getting paid more, with Jeffrey Baxter having the highest compensation of 1,379,630$.
Steven Gillis is 67, he's been the Independent Chairman of the Board of VBI Vaccines since 2016. There are 1 older and 18 younger executives at VBI Vaccines. The oldest executive at VBI Vaccines Inc. is Michel Wilde, 70, who is the Independent Director.
Steven's mailing address filed with the SEC is C/O VBI VACCINES INC.,, 160 SECOND STREET, FLOOR 3, CAMBRIDGE, MA, 02142.
Over the last 8 years, insiders at VBI Vaccines have traded over 18,633,012$ worth of VBI Vaccines stock and bought 55,142,222 units worth 66,770,591$ . The most active insiders traders include Advisors Llcperceptive Life...、Tomer Kariv、Steven D Rubin. On average, VBI Vaccines executives and independent directors trade stock every 62 days with the average trade being worth of 130,457$. The most recent stock trade was executed by Steven Gillis on 10 July 2023, trading 609,090 units of VBIV stock currently worth 1,004,999$.
vbi vaccines inc. (nasdaq: vbiv) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. vbi’s evlp vaccine platform allows for the design of enveloped (“e”) virus-like particle (“vlp”) vaccines that closely mimic the target virus. the company’s lead evlp asset is a prophylactic cytomegalovirus (cmv) vaccine; vbi has initiated work for gmp manufacturing of its cmv candidate for use in formal preclinical and phase i trials. the company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. vbi has completed proof of concept thermostability studies on a number of vaccine and biologic targets. vbi is headquartered in cambridge, ma with research facilities in ottawa, canada.
VBI Vaccines executives and other stock owners filed with the SEC include: